Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies
Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals
Scientific Process
“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says
Reviewers Note Major Flaws In Design Of Burzynski’s Trials
Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”
Case Study: The Post-Surgical Treatment Of A Child With Medulloblastoma At The Burzynski Clinic
Trending Stories
- House passes three-year extension of ACA subsidies with bipartisan support
- A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?
- MSK’s AML researcher Bayard “Barney” Clarkson, former president of ASCO and AACR, dies at 99
- NIH agrees to review hundreds of denied or shelved grant applications
- Patient advocate David Mitchell, 75, dies of multiple myeloma
- Paul Engstrom, Fox Chase pioneer of cancer prevention, dies at 89









